Table 1:
Description of the main analysis database of 612 unique lesions (benign lesions and hormone receptor positive/HER2 negative (HR+/HER2−) cancers imaged at either 1.5 T or 3.0 T): number of cases, patient age, TNM staging size, and maximum lesion size by lesion type and field strength of the image acquisition (CI = confidence interval). TNM staging size is from the primary tumor, lymph node, and metastasis (TNM) classification of the American Joint Commission of Cancer (AJCC) [25].
| Number of lesions at field strength of image acquistion |
Patient age* (Median [95% CI], years) |
maximum lesion size (radiomic feature S4) (Median, [95% CI], mm) |
TNM staging size Number of lesions (% of lesion type by field strength) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lesion type |
1.5 T |
3.0 T |
Total | 1.5 T | 3.0 T | 1.5 T | 3.0 T | 1.5 T | 3.0 T | |
| Benign | 150 | 99 | 249 | 49 [25, 73] | 47 [32, 74] | 12.7 [5.3, 56.3] | 13.0 [5.5, 54.1] | T1 (≤ 20 mm) | 112 (75%) | 72 (73%) |
| T2 (20 mm ≥ 50 mm | 32 (21%) | 24 (24%) | ||||||||
| T3 (> 50 mm) | 6 (4%) | 3 (3%) | ||||||||
| HR+ / HER2− | 223 | 140 | 363 | 58 [35, 83] | 55 [38, 80] | 24.9 [8.3, 96.4] | 22.6 [5.2, 87.4] | T1 (≤ 20 mm) | 83 (37%) | 63 (45%) |
| T2 (20 mm ≥ 50 mm | 105 (47%) | 61 (44%) | ||||||||
| T3 (> 50 mm) | 35 (16%) | 16 (11%) | ||||||||
| Total | 373 | 239 | 612 | |||||||
*
Patient age was not available for 33 out of 150 benign lesions imaged at 1.5 T (22%), 13 out of 99 benign lesions imaged at 3.0 T (13%), 22 out of 223 HR+/HER2−cancers imaged at 1.5 T (10%), and 10 out of 140 HR+/HER2−cancers imaged at 3.0 T (7%).